RNA Technologies Expand Tool Kit for Cancer Immunotherapy
Elie Dolgin • October 1, 2019
Multiple companies are pursuing mRNA-based medicines that harness the body's protein-making machinery to transform lab-synthesized nucleotides into cancer-associated antigens, in the case of vaccines, or immune-stimulating molecules, in the case of therapeutics. Several candidates from BioNTech and Moderna have shown promise in early-stage testing.
Continue reading at Cancer Discovery.
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.